Valdecoxib

Valdecoxib is a COX-2 inhibitor used to treat osteoarthritis and dysmenorrhoea. Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

Chemical structure of Valdecoxib
Mechanism
Curator reviewed
Primary indication
For the treatment of osteoarthritis and dysmenorrhoeaCurator reviewed · 3 structured indications
Formula / weight
C16H14N2O3S · 314.359 g/mol (avg)
First approval
United States, 2001
Brand names
  • Bextra

Resolves to

Structure
InChIKeyLNPDTQAFDNKSHK-UHFFFAOYSA-NSMILESCC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,886Drug interactionsStructured to mechanism, not free text
Sign in
26Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
35Marketed productsAcross 3 countries and 6 labellers
Sign in
2ATC codesIncluding every combination product, plus 34 drug categories
Sign in
26+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Valdecoxib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account